Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Toxins
|
January 24, 2025
Does Clostridium Perfringens Epsilon Toxin Mimic an Auto-Antigen Involved in Multiple Sclerosis?
Marie-Lise Gougeon, Valérie Seffer, Cezarela Hoxha, et al.
Frontiers in Immunology
|
November 16, 2020
Zika Virus Inhibits IFN-α Response by Human Plasmacytoid Dendritic Cells and Induces NS1-Dependent Triggering of CD303 (BDCA-2) Signaling
Sandra Bos, Béatrice Poirier-Beaudouin, Valérie Seffer, et al.
Plos One
|
April 3, 2014
Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells
Emily Loison, Béatrice Poirier-Beaudouin, Valérie Seffer, et al.
Toxins
|
February 26, 2026
<i>Clostridioides difficile</i> Immunity During Pregnancy and Passive Antibody Transfer to Neonates from Cord Blood and Breast Milk
Alban Le Monnier, Claire de Curraize, Valérie Seffer, et al.
Vaccine
|
September 30, 2017
CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles
Catherine Goujon, Marie-Lise Gougeon, Laura Tondeur, et al.
Plos Pathogens
|
April 22, 2026
Modeling neonatal immune response to B. pertussis identifies early B cell activation and differentiation
Soraya Matczak, Mirko Sadi, Pauline Leroux, et al.
Heliyon
|
February 23, 2017
HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND)
Marie-Lise Gougeon, Béatrice Poirier-Beaudouin, Jacques Durant, et al.
Heliyon
|
April 4, 2017
Erratum to 'HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)'
Marie-Lise Gougeon, Béatrice Poirier-Beaudouin, Jacques Durant, et al.
Vaccine
|
January 13, 2009
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial
Odile Launay, Christine Sadorge, Nathalie Jolly, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Toxins
|
January 24, 2025
Does Clostridium Perfringens Epsilon Toxin Mimic an Auto-Antigen Involved in Multiple Sclerosis?
Marie-Lise Gougeon, Valérie Seffer, Cezarela Hoxha, et al.
Frontiers in Immunology
|
November 16, 2020
Zika Virus Inhibits IFN-α Response by Human Plasmacytoid Dendritic Cells and Induces NS1-Dependent Triggering of CD303 (BDCA-2) Signaling
Sandra Bos, Béatrice Poirier-Beaudouin, Valérie Seffer, et al.
Plos One
|
April 3, 2014
Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells
Emily Loison, Béatrice Poirier-Beaudouin, Valérie Seffer, et al.
Toxins
|
February 26, 2026
<i>Clostridioides difficile</i> Immunity During Pregnancy and Passive Antibody Transfer to Neonates from Cord Blood and Breast Milk
Alban Le Monnier, Claire de Curraize, Valérie Seffer, et al.
Vaccine
|
September 30, 2017
CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles
Catherine Goujon, Marie-Lise Gougeon, Laura Tondeur, et al.
Plos Pathogens
|
April 22, 2026
Modeling neonatal immune response to B. pertussis identifies early B cell activation and differentiation
Soraya Matczak, Mirko Sadi, Pauline Leroux, et al.
Heliyon
|
February 23, 2017
HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND)
Marie-Lise Gougeon, Béatrice Poirier-Beaudouin, Jacques Durant, et al.
Heliyon
|
April 4, 2017
Erratum to 'HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)'
Marie-Lise Gougeon, Béatrice Poirier-Beaudouin, Jacques Durant, et al.
Vaccine
|
January 13, 2009
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial
Odile Launay, Christine Sadorge, Nathalie Jolly, et al.
Page
of 1